Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancer: LAGOON trial tests powerful drug combo

NCT ID NCT05153239

Disease control Sponsor: PharmaMar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 7 times

Summary

This study tested two new treatments for people with small cell lung cancer that came back after initial chemotherapy. The experimental drugs, lurbinectedin alone or with irinotecan, were compared to standard treatments (topotecan or irinotecan). The goal was to see if the new options help patients live longer. The trial involved 705 adults whose cancer had progressed after one prior platinum-based treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

705 people

The number who actually took part.

Started

Jul 2022

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntary written informed consent of the patient obtained before any study-specific procedure 2. Age≥18 years 3. Histologically or cytologically confirmed diagnosis of SCLC. 4. One prior line of platinum-containing chemotherapy with/without anti-PD-1 or anti-PD-L1 (Note: at least 70% of patients included in the study have to be pretreated with anti-PD-1 or anti-PD-L1) 5. Chemotherapy-free interval (CTFI, time from the last dose of first-line platinum-containing chemotherapy to the occurrence of progressive disease) ≥ 30 days (independent of the immunotherapy maintenance, if applicable) 6. Patients with history of Central Nervous System (CNS) metastases can participate provided they are pretreated and radiologically stable (i.e., without evidence of progression) for at least 4 weeks by repeated imaging (note: repeated imaging should be performed during study screening), asymptomatic, and without requirement of steroid treatment for at least 7 days before the first dose of study treatment 7. Eastern Cooperative Oncology Group (ECOG) PS ≤ 2 8. Adequate hematological, renal, metabolic and hepatic function: 1. Hemoglobin ≥ 9.0 g/dL \[patients may have received prior red blood cell (RBC) transfusion, if clinically indicated\]; absolute neutrophil count (ANC) ≥ 2.0 x 10\^9/L, and platelet count ≥ 100 x 10\^9/L. 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN). 3. Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN. 4. Albumin ≥ 3.0 g/dL. 5. Calculated creatinine clearance (CrCL) ≥ 30 mL/min (using Cockcroft and Gault's formula). 9. At least three weeks since last prior antineoplastic treatment and recovery to grade ≤ 1 from any adverse event (AE) related to previous anticancer treatment (excluding sensory neuropathy, immune-related hypothyroidism, anemia, asthenia and alopecia, all grade ≤ 2) according to the National Cancer InstituteCommon Terminology Criteria for Adverse Events (NCICTCAE) v.5. 10. Prior radiotherapy (RT): At least two weeks since completion of prophylactic cranial irradiation (PCI), and to any other site not previously specified. 11. Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to seven months after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product (IMP) dose. Exclusion Criteria: 1. Platinum-naïve patients or patients pretreated with more than one prior chemotherapy regimen (including patients re-challenged with same initial regimen). 2. Prior treatment with lurbinectedin, trabectedin, PM14, or topoisomerase I inhibitors (irinotecan, topotecan, etc.). 3. Active or untreated CNS metastases and/or carcinomatous meningitis. 4. Patients with limited-stage disease who are candidates for local or regional therapy, including PCI, thoracic RT or both, must have been offered that option and completed treatment or refused it prior to randomization. 5. Concomitant diseases/conditions: 1. History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year. 2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment. 3. Ongoing chronic alcohol consumption or cirrhosis with Child-Pugh score B or C. 4. Known Gilbert's disease. 5. Active uncontrolled infection. Serious non-healing wound, ulcer or bone fracture. Presence of external drainages. 6. Ongoing, treatment-requiring, non-neoplastic chronic liver disease of any origin. For Hepatitis B, this includes positive tests for both Hepatitis B surface antigen (HBsAg) and quantitative Hepatitis B polymerase chain reaction (PCR). For Hepatitis C, this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR. Subjects taking hepatitis related antiviral therapy within six months prior to the first dose of study drugs will also be excluded. 7. Intermittent or continuous oxygen requirement within two weeks prior to randomization. Patients with confirmed or suspected diagnosis of diffuse interstitial lung disease or pulmonary fibrosis. 8. Patients with a second invasive malignancy treated with chemotherapy and/or RT. Patients with a previous malignancy that was completely resected with curative intention three or more years prior to randomization, except treated in situ carcinoma of the cervix, basal or squamous cell skin carcinoma, and in situ transitional cell bladder carcinoma and who has been continuously in remission since then will be permitted. 9. Limitation of the patient's ability to comply with the treatment or to follow the protocol. 10. Documented or suspected invasive fungal infections requiring systemic treatment within 12 weeks of randomization. 11. Known human immunodeficiency virus (HIV) infection. 12. Any past or present chronic inflammatory colon and/or liver disease, past intestinal obstruction, pseudo or subocclusion or paralysis. 13. Evident symptomatic pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days. 14. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study (e.g.; COVID-19 disease). 6. RT in more than 35% of the bone marrow. 7. History of previous bone marrow and/or stem cell transplantation and allogenic transplant. 8. Patient has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of inactivated vaccines is allowed. 9. Impending need for RT (e.g., painful bone metastasis and/or risk of spinal cord compression). 10. History of allergy or hypersensitivity to any of the study drugs or any of their excipients. 11. Women who are pregnant or breast feeding and fertile patients (men and women) who are not able to use a highly effective method of contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed small cell lung cancer

Contacts and locations

Locations

  • A.O. SS. Antonio e Biagio e Cesare Arrigo di Alessandria

    Alessandria, 15121, Italy

  • A.O. Santa Croce e Carle, Ospedale Carle

    Cuneo, 12100, Italy

  • AOU Careggi

    Florence, 50134, Italy

  • ASL 3 Genovese Oncologia Medica Villa Scassi

    Genova, 16149, Italy

  • ASST Sette Laghi

    Varese, 21100, Italy

  • ASST Valtellina e Alto Lario Ospedale di Sondrio

    Sondrio, 23100, Italy

  • Aalborg University Hospital

    Aalborg, 9000, Denmark

  • Algemeen Ziekenhuis AZ Klina - Borstkliniek

    Brasschaat, 2930, Belgium

  • Antwerp University Hospital

    Edegem, Antwerp, 2650, Belgium

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Asklepios Fachklinik München-Gauting

    Gauting, 82131, Germany

  • AssAP-HP - Hopital Ambroise-Pare

    Boulogne-Billancourt, 92100, France

  • Austin Hospital- Medical Oncology Unit

    Heidelberg, VIC 3084, Australia

  • Az Sint Maarten Mechelen

    Mechelen, 2800, Belgium

  • Azienda Ospedaliera Univ. Policlinico G Rodolico San Marco

    Catania, 95125, Italy

  • Azienda Ospedaliero Universitaria delle Marche

    Ancona, 60126, Italy

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    Orbassano, 10043, Italy

  • Azienda USL di Piacenza

    Piacenza, 29121, Italy

  • BRICC - Ballarat Health Services

    Ballarat Central, Victoria, 3350, Australia

  • Bacs-Kiskun County Hospital

    Kecskemét, 6000, Hungary

  • Bagcilar Medipol Mega University Hospital

    Bağcılar, Istanbul, 34214, Turkey (Türkiye)

  • Belfast Health and Social Care Trust

    Belfast, BT9 7AB, United Kingdom

  • Bichat-Claude Bernard Hospital

    Paris, 75018, France

  • Box Hill Hospital Eastern Health Clinical School

    Box Hill, Victoria, 3128, Australia

  • Buddhist Dalin Tzu Chi Hospital

    Dalin, Chiayi, 622401, Taiwan

  • CHA Bundang Medical Center, CHA University

    Gyeonggi-do, 13496, South Korea

  • CHR de la Citadelle

    Liège, 4000, Belgium

  • CHU Liege

    Liège, 4000, Belgium

  • CHU Reims - Hpital Maison Blanche

    Reims, 51092, France

  • CHU de Caen - Hopital Cote de Nacre

    Caen, 14033, France

  • CHU de Nantes

    Nantes, Cedex 01 44093, France

  • CISSS de la Montérégie-Centre - Hôpital Charles LeMoyne

    Longueuil, Quebec, J4V 2H1, Canada

  • Cancer Care Wollongong

    Wollongong, NSW 2500, Australia

  • Center Hospital of the National Center for Global Health and Medicine

    Shinjuku-Ku, Tokyo, 162-8655, Japan

  • Centre François Baclesse

    Caen, 14000, France

  • Centre Hospitalier Chretien CHC - MontLegia

    Liège, 4000, Belgium

  • Centre Hospitalier Intercommunal de Creteil (CHIC)

    Créteil, 94000, France

  • Centre Hospitalier Universitaire (CHU) Ambroise Pare

    Mons, 7000, Belgium

  • Centre Hospitalier Universitaire CHU De Limoges

    Limoges, 87000, France

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, 1011, Switzerland

  • Centro de Estudios Clínicos SAGA

    Santiago, Chile

  • Centrul de Oncologie Sfantu Nectarie

    Craiova, 200746, Romania

  • Changhua Christian Hospital

    Chang-hua, Chang Hua, 500, Taiwan

  • Chungbuk National University Hospital

    Cheongju-si, 28644, South Korea

  • Clatterbridge Hospital

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

  • Clinica Alemana de Santiago

    Santiago, Chile

  • Clinical Research Chile SpA

    Valdivia, Los Ríos Region, 5090000, Chile

  • Clínica Santa María

    Santiago, Chile

  • Clínica Universidad de Navarra

    Madrid, Madrid, 28027, Spain

  • Clínica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Complejo Hospitalario Materno-Insular de Gran Canaria

    Las Palmas de Gran Canaria, Gran Canaria, 35016, Spain

  • Complex Oncology Center - Plovdiv EOOD, First Department of Medical Oncology and Oncological Diseases in Gastroenterology

    Plovdiv, 4000, Bulgaria

  • Complexo Hospitalario Universitario De Vigo (CHUVI) - Hospital Xeral

    Vigo, Pontevedra, 36312, Spain

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Debreceni Egyetem - Klinikai Kozpont

    Debrecen, 4032, Hungary

  • Duly Health and Care

    Joliet, Illinois, 60435, United States

  • Evangelische Lungenklinik Berlin

    Berlin, 13125, Germany

  • FirstHealth Outpatient Cancer Center

    Pinehurst, North Carolina, 28374, United States

  • Florida Cancer Specialists - East

    West Palm Beach, Florida, 33401, United States

  • Florida Cancer Specialists - North

    St. Petersburg, Florida, 33705, United States

  • Florida Cancer Specialists - Panhandle

    Tallahassee, Florida, 32308, United States

  • Florida Cancer Specialists - South

    Fort Myers, Florida, 33901, United States

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Roma, 00128, Italy

  • Froedtert Hospital/Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor

    Barretos, SP 14784-400, Brazil

  • Fundación Arturo López Pérez

    Santiago, Chile

  • Gachon University Gil Medical Center

    Incheon, 21565, South Korea

  • Genesis Cancer and Blood

    Hot Springs, Arkansas, 71913, United States

  • Gosford Hospital GH - Central Coast Cancer Centre

    Gosford, 2250, Australia

  • Goztepe Prof. Dr. Suleyman Yalcin City Hospital

    Kadıköy, Istanbul, 34722, Turkey (Türkiye)

  • Grand Hopital de Charleroi GHdC - Hopital Saint Joseph

    Charleroi, 6000, Belgium

  • Gustave Roussy

    Villejuif, 94805, France

  • Guys and St Thomas NHS Foundation Trust

    London, SE1 9RT, United Kingdom

  • HFR Freiburg Kantonsspital

    Villars-sur-Glâne, 1752, Switzerland

  • Hamilton Health Sciences -Juravinski Cancer Centre

    Hamilton, Ontario, L8V 5C2, Canada

  • Helios St. Johannes Klinikum

    Duisburg, 74166, Germany

  • Hetenyi G Korhaz, Onkologiai Kozpont

    Szolnok, 5004, Hungary

  • High Technology Hospital Medcenter

    Batumi, 6000, Georgia

  • Hirosaki University Hospital

    Hirosaki, Aomori, 036-8563, Japan

  • Hopital Civil / Nouvel Hopital Civil

    Strasbourg, 67091, France

  • Hopital Jean Minjoz

    Besançon, 25030, France

  • Hopital Morvan CHU de Brest

    Brest, 29200, France

  • Hospital Clinico Universidad de Chile

    Santiago, Chile

  • Hospital Clínico San Carlos

    Madrid, Madrid, 28040, Spain

  • Hospital Clínico Universitario Lozano Bleza

    Zaragoza, Zaragoza, 50009, Spain

  • Hospital Clínico Universitario de Valladolid

    Valladolid, Valladolid, 47003, Spain

  • Hospital Foch

    Suresnes, 92150, France

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, 28007, Spain

  • Hospital Regional Universitario Málaga Hospital Civil

    Málaga, Málaga, 29010, Spain

  • Hospital Sao Lucas da PUCRS

    Porto Alegre, Porto Alegre, 90610-000, Brazil

  • Hospital Teresa Herrera C.H.U.A.

    A Coruña, A Coruña, 15009, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, 08035, Spain

  • Hospital Universitari i Politècnic La Fe

    Valencia, Valencia, 46026, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario Fundación Jimenez Díaz

    Madrid, Madrid, 28040, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Madrid, 28050, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, 28006, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Lugo, 27003, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, 28034, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, Córdoba, 14004, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Sevilla, 41013, Spain

  • Hôpital de la Cité-de-la- Santé

    Laval, Quebec, H7M 3L9, Canada

  • IFO Regina Elena

    Roma, 00128, Italy

  • II Klinika Chorob Pluc i Gruzlicy

    Bialystok, 15-569, Poland

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola Malpighi Oncologia medica

    Bologna, 40138, Italy

  • IRCCS Centro di Riferimento Oncologico

    Aviano, 33081, Italy

  • IRCCS Istituto Clinico Humanitas - Cancer Center

    Milan, 20089, Italy

  • Inha University Hospital

    Incheon, 22332, South Korea

  • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Institut Català d Oncologia (ICO) - Hospital Germans Trias i Pujol

    Badalona, Barcelona, 08916, Spain

  • Institute Of Clinical Oncology

    Tbilisi, 156, Georgia

  • Instituto Nacional de Cancer - Ministrio da Sade

    Rio de Janeiro, 20231-050, Brazil

  • Irccs-Crob

    Rionero in Vulture, 85028, Italy

  • Irmandade daSanta Casa de Misericordia de Porto Alegre

    Porto Alegre, Porto Alegre, 90050-170, Brazil

  • Ironwood Cancer & Research Centers

    Chandler, Arizona, 85224, United States

  • Istituto Oncologico della Svizzera Italiana

    Bellinzona, 6500, Switzerland

  • Izumi City General Hospital

    Izumi, Osaka, 594-0073, Japan

  • JSC Evex Hospitals "Caraps Medline"

    Tbilisi, 179, Georgia

  • James Lind Centro de Investigación del Cáncer

    Temuco, Araucania, 4780000, Chile

  • Kanagawa Cancer Center

    Izumi, Osaka, 594-0073, Japan

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, 920-8641, Japan

  • Kangbuk Samsung Hospital

    Seoul, 03181, South Korea

  • Kansai Medical University Hospital

    Hirakata-shi, Osaka, 573-1191, Japan

  • Kantonsspital Baselland

    Liestal, 4410, Switzerland

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Kaohsiung, 83301, Taiwan

  • Kishiwada City Hospital

    Kishiwada, Osaka, 596-8501, Japan

  • Klinik Loewenstein gGmbH

    Löwenstein, 74245, Germany

  • Klinikum Bremen Ost

    Bremen, 28325, Germany

  • Klinikum Esslingen GmbH

    Esslingen am Neckar, 73730, Germany

  • Klinikum Kassel - Medizinische Klinik IV

    Kassel, 34125, Germany

  • Kobe City Medical Center General Hospital

    Kobe, Hyōgo, 650-0047, Japan

  • Kocaeli University Hospital

    İzmit, Kocaeli, 41380, Turkey (Türkiye)

  • Krankenhaus Martha-Maria Halle gGmbH

    Halle, 06120, Germany

  • Kyushu University Hospital

    Fukuoka, Fukuoka, 812-8582, Japan

  • LTD Cancer Research Centre

    Tbilisi, 186, Georgia

  • Liv Hospital Ankara

    Çankaya, Ankara, 06680, Turkey (Türkiye)

  • LungenClinic Grosshansdorf

    Großhansdorf, Schleswig-Holstein, 22927, Germany

  • MD Anderson Cancer Center

    Madrid, Madrid, 28033, Spain

  • McGill University Health Centre (MUHC)

    Montreal, H4A 3J1, Canada

  • Medicalpark Seyhan Hospital

    Seyhan, Adana, 01140, Turkey (Türkiye)

  • Medisprof srl

    Cluj-Napoca, 400641, Romania

  • Medizinische Universitaet Wien

    Vienna, A-1090, Austria

  • Mrukmed. Lekarz Beata Madej-Mruk i Partner. Sp.p

    Rzeszów, 35-021, Poland

  • MultiCare Regional Cancer Center - Tacoma

    Tacoma, Washington, 98405, United States

  • Multiprofile Hospital for Active Treatment - Uni Hospital OOD Department of Medical Oncology

    Panagyurishte, Panagyurishte, 4500, Bulgaria

  • Multiprofile Hospital for Active Treatment Serdika EOOD Second Department of Medical Oncology

    Sofia, 1632, Bulgaria

  • National Taiwan University Cancer Center

    Taipei, 106, Taiwan

  • New Hospitals

    Tbilisi, 114, Georgia

  • Northern Beaches Hospital

    Frenchs Forest, NSW 2086, Australia

  • Norton Cancer Institue, Downtown

    Louisville, Kentucky, 40202, United States

  • Nottingham University Hospitals NHS Trust

    Nottingham, NG5 1PB, United Kingdom

  • Nucleo de Oncologia da Bahia - NOB

    Ondina, Salvador, BA 40170-110, Brazil

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia Ltda

    Ijuí, 98700-00, Brazil

  • Ohara HealthCare Foundation Kurashiki Central Hospital

    Kurashiki, Okayama-ken, 710-8602, Japan

  • Oncocenter Oncologie clinica S.R.L

    Timișoara, 300166, Romania

  • Oncocentro-Centro de Oncologia do Parana

    Curitiba, Paraná, 82305-100, Brazil

  • Oncolab SRL

    Craiova, 200385, Romania

  • Oncologia Medica II Istituto Oncologico Veneto IRCCS

    Padova, 35128, Italy

  • Oncology Hematology West, PC (Grand Island)

    Grand Island, Nebraska, 68803, United States

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists

    Omaha, Nebraska, 68130, United States

  • Osaka Habikino Medical Center

    Habikino, Osaka, Japan

  • Ospedale Maggiore di Novara

    Novara, 28100, Italy

  • Ovidius Clinical Hospital

    Ovidiu, 9005900, Romania

  • Pulmonology Hospital Torokbalint

    Törökbálint, 2045, Hungary

  • Rabin Medical Center

    Petah Tikva, 49100, Israel

  • Rambam Health Care Campu

    Haifa, 3109601, Israel

  • Sana Klinikum Offenbach

    Offenbach, 63069, Germany

  • Sc Oncopremium Team Srl

    Baia Mare, 020945, Romania

  • Sendai Kousei Hospital

    Sendai, Miyagi, 980-0873, Japan

  • Seoul Metropolitan Government-Seoul National University Boramae Medical Center

    Seoul, 07061, South Korea

  • Shaare Zedek Medical Center

    Jerusalem, 9103102, Israel

  • Sjællands Universitetshospital

    Næstved, 4700, Denmark

  • Southlake Regional Health Centre

    Newmarket, Ontario, L3Y 2P9, Canada

  • Specialized hospital for active treatment of oncological diseases

    Sofia, 1303, Bulgaria

  • Specjalistyczna Praktyka Lekarska Slawomir Mandziuka

    Lublin, 20-093, Poland

  • Specjalistyczny Szpital Onkologiczny NU-MED sp. Z

    Tomaszów Mazowiecki, 97-200, Poland

  • Spital Thurgau - Kantonspital Frauenfeld

    Frauenfeld, 8501, Switzerland

  • Spital Thurgau - Kantonsspital Muensterlingen

    Münsterlingen, 8596, Switzerland

  • St John of God Murdoch Hospital

    Murdoch, WA 6150, Australia

  • Staedtisches Klinikum München - Bogenhausen

    München, 81925, Germany

  • Szpital Specjalistyczny w Prabutach Sp. z o.o

    Prabuty, 82-550, Poland

  • Szpitale Pomorskie Sp. z o.o., Oddzial Onkologii K

    Gdynia, 81-519, Poland

  • Sønderborg Sygehus

    Sønderborg, 6400, Denmark

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 6423906, Israel

  • The Cancer Institute Hospital Of JFCR

    Koto-Ku, Tokyo, 135-8550, Japan

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, 06591, South Korea

  • The Catholic University of Korea, St.Vincents Hospital

    Gyeonggi-do, 16247, South Korea

  • The Chaim Sheba Medical Center

    Ramat Gan, Israel

  • The Chris Obrien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The Princess Alexandra Hospital

    Harlow, CM20 1QX, United Kingdom

  • The Royal Wolverhampton NHS Trust

    Wolverhampton, WV10 0QP, United Kingdom

  • Thoraxclinic Heidelberg GmbH

    Heidelberg, 69126, Germany

  • Todua Clinic

    Tbilisi, 112, Georgia

  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

    Bunkyō-Ku, Tokyo, Japan

  • UPCO - Hospital de Clinicas de Porto Alegre

    Santa Cecília, Porto Alegre, RS 90035-903, Brazil

  • Universita degli Studi della Campania Luigi Vanvitelli

    Naples, 80138, Italy

  • Universitaetsklinikum Halle Saale

    Halle, 06120, Germany

  • Universitaetsmedizin Mannheim

    Mannheim, 68167, Germany

  • Universittsklinikum Freiburg

    Freiburg im Breisgau, 79106, Germany

  • University Health Network - Princess Margaret Hospital

    Toronto, ON M5G 2C1, Canada

  • University Hospital Basel

    Basel, 4031, Switzerland

  • University Hospital Salzburg

    Salzburg, A-5020, Austria

  • Utah Cancer Specialists

    Salt Lake City, Utah, 84106, United States

  • Vejle Hospital

    Vejle, 7100, Denmark

  • Veszprem Megyei Tudogyogyintezet Farkasgyepu

    Farkasgyepű, 8582, Hungary

  • Vincentius-Diakonissen-Kliniken gAG Karlsruhe

    Karlsruhe, 76137, Germany

  • Wojewódzkie Wielospecjalistyczne Centrum Onkologii

    Lodz, 93-513, Poland

  • Zentralklinik Bad Berka GmbH

    Bad Berka, 99437, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.